Overview

Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) when used in patients with type 2 diabetes mellitus (T2DM) and moderate or severe renal insufficiency.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Vildagliptin